Equities research analysts expect Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to announce ($0.75) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Dicerna Pharmaceuticals’ earnings. The highest EPS estimate is ($0.71) and the lowest is ($0.81). Dicerna Pharmaceuticals posted earnings of ($0.68) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 10.3%. The company is expected to announce its next quarterly earnings results on Monday, November 6th.

Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.54). The company had revenue of $0.25 million for the quarter, compared to analysts’ expectations of $0.08 million. Dicerna Pharmaceuticals had a negative return on equity of 168.65% and a negative net margin of 8,474.12%. The firm’s revenue for the quarter was up 2400.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.75) EPS.

A number of analysts have issued reports on DRNA shares. ValuEngine downgraded Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Zacks Investment Research downgraded Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. Finally, Chardan Capital reiterated a “hold” rating on shares of Dicerna Pharmaceuticals in a report on Monday, August 14th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. Dicerna Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $4.69.

A number of large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its position in Dicerna Pharmaceuticals by 2.4% in the first quarter. Renaissance Technologies LLC now owns 418,500 shares of the biopharmaceutical company’s stock valued at $1,423,000 after acquiring an additional 9,818 shares during the last quarter. Sabby Management LLC boosted its stake in Dicerna Pharmaceuticals by 100.0% in the first quarter. Sabby Management LLC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $680,000 after acquiring an additional 100,000 shares in the last quarter. Paloma Partners Management Co boosted its stake in Dicerna Pharmaceuticals by 49.7% in the first quarter. Paloma Partners Management Co now owns 160,000 shares of the biopharmaceutical company’s stock valued at $544,000 after acquiring an additional 53,131 shares in the last quarter. UBS Group AG boosted its stake in Dicerna Pharmaceuticals by 0.6% in the first quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock valued at $968,000 after acquiring an additional 1,599 shares in the last quarter. Finally, Bourgeon Capital Management LLC boosted its stake in Dicerna Pharmaceuticals by 188.9% in the second quarter. Bourgeon Capital Management LLC now owns 39,000 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 25,500 shares in the last quarter. Hedge funds and other institutional investors own 55.49% of the company’s stock.

Shares of Dicerna Pharmaceuticals (NASDAQ DRNA) traded up 1.72% on Wednesday, reaching $6.51. 388,790 shares of the company’s stock were exchanged. The firm’s market capitalization is $135.69 million. Dicerna Pharmaceuticals has a one year low of $2.42 and a one year high of $6.66. The firm has a 50 day moving average of $3.90 and a 200 day moving average of $3.40.

COPYRIGHT VIOLATION WARNING: This story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/10/04/dicerna-pharmaceuticals-inc-drna-expected-to-post-earnings-of-0-75-per-share.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.